Paige OmniScreen

Overview of Paige OmniScreen

Paige OmniScreen is an advanced AI-powered module designed to predict a broad spectrum of clinically relevant molecular biomarkers across multiple cancer types directly from H&E tissue.

• Can predict 1,600+ biomarkers and link phenotypes with genetic patterns
• Replicates a targeted biomarker gene panel of 491 genes and growing
• 5-minute turnaround time powers timely clinical decision-making

OmniScreen Use Cases

• Power Research & Development:
• Comprehensive, cost-effective analysis of extensive datasets accelerates the discovery of new indications and therapeutic targets
• Maximize Insights for Early Phase Trials:
• Leverage AI to gain valuable insight from H&E without requiring large datasets or additional tissue samples
• Optimize Patient Selection:
• Identify patients who may harbor genomic alterations required for trial participation
• Streamline recruitment and saving the time and resources currently devoted to enrolling unsuitable candidates
• Drive Commercialization:
• Bridge the NGS testing care gap by providing a cheaper and faster method of genomic profiling
• Enable more efficient identification of patients for targeted therapy and make precision medicine more accessible and affordable

Key Benefits from OmniScreen:

• Accelerate Clinical Trials: Fast-track patients to appropriate downstream testing and interventional clinical trials, driving speed and new efficiency
• Speed clinical decision-making: Prioritize molecular testing for patients most likely to harbor a mutation and make informed therapy decisions quickly based on AI insights
• Cut costs: potential to save millions by pre-screening to eliminate unnecessary molecular tests when the AI indicates no mutation is present
• Conserve Precious Tissue: Send only those patients with AI-detected genetic mutations to molecular testing, and save tissue samples for high-impact testing